Dihydroergotamine
- Generic Name
- Dihydroergotamine
- Brand Names
- Dhe-45, Migranal, Trudhesa
- Drug Type
- Small Molecule
- Chemical Formula
- C33H37N5O5
- CAS Number
- 511-12-6
- Unique Ingredient Identifier
- 436O5HM03C
- Background
A 9,10alpha-dihydro derivative of ergotamine. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile.
Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity. The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product.
- Indication
Dihydroergotamine (DHE) in all formulations is indicated for the acute treatment of migraine with or without aura in adults. As an injection, DHE is also indicated for the acute treatment of cluster headache episodes.
DHE is not indicated for migraine prevention or the management of hemiplegic or basilar migraine.
- Associated Conditions
- Cluster Headache, Migraine Headache, With or Without Aura
QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-08-31
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Allergan
- Target Recruit Count
- 54
- Registration Number
- NCT01191723
- Locations
- 🇺🇸
Cetero Research, Fargo, North Dakota, United States
Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure
- Conditions
- Healthy
- Interventions
- Drug: IV Placebo (Saline)Drug: Placebo Inhaler
- First Posted Date
- 2010-03-18
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Allergan
- Target Recruit Count
- 24
- Registration Number
- NCT01089062
- Locations
- 🇺🇸
Duke Clinical Research Unit, Durham, North Carolina, United States
Phase 3 Study of MAP0004 in Adult Migraineurs
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Allergan
- Target Recruit Count
- 902
- Registration Number
- NCT00623636
- Locations
- 🇺🇸
Swedish Pain and Headache Clinic, Seattle, Washington, United States
A Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine
- Conditions
- Migraine
- Interventions
- First Posted Date
- 2006-06-12
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 64
- Registration Number
- NCT00335777
- Locations
- 🇺🇸
Jefferson Headache Center, Philadelphia, Pennsylvania, United States
A Study Examining the Use of a Migraine Medicine in the Treatment of Two Migraine Attacks in Patients Who Have Increased Skin Sensitivity
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 13
- Registration Number
- NCT00203268
- Locations
- 🇺🇸
Jefferson Headache Center, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.